Per Sonne Holm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Per Sonne Holm has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Roman Nawroth
Technical University of Munich
50 shared publications - Sebastian Johannes Schober
Department of Pediatrics, Children’s Cancer Research Center, Kinderklinik München Schwabing, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany
48 shared publications - Andreas Kolk
Department of Oral and Maxillofacial Surgery, Medical University of Innsbruck, A-6020 Innsbruck, Austria
47 shared publications - Anna Josefine von Ofen
Department of Pediatrics, Children's Cancer Research Center, Kinderklinik München Schwabing, School of Medicine, Technical University of Munich, Munich, Germany
47 shared publications - Caroline Schoening
Department of Pediatrics, Children's Cancer Research Center, Kinderklinik München Schwabing, School of Medicine, Technical University of Munich, Munich, Germany
47 shared publications - Charlotte Middendorf
Department of Pediatrics, Children's Cancer Research Center, Kinderklinik München Schwabing, School of Medicine, Technical University of Munich, Munich, Germany
47 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Supplemental Figure 4: Combination of XVir-N-31 and CDK4/6 inhibitor LEE011 induces an abscopal effect, induces monocyte infiltration and increases M1/M2 macrophage ratio in injected tumors.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Supplemental Figure 4: Combination of XVir-N-31 and CDK4/6 inhibitor LEE011 induces an abscopal effect, induces monocyte infiltration and increases M1/M2 macrophage ratio in injected tumors.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Supplemental Figure 3: Characterization of tumor-infiltrating T cells at the end of experiment (A673 xenografts).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Supplemental Figure 3: Characterization of tumor-infiltrating T cells at the end of experiment (A673 xenografts).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Supplemental Figure 2: Combination of XVir-N-31 (XVir) and CDK4/6 inhibitor LEE011 (LEE) increases viral replication and immunogenicity of xenografted EwS tumors in vivo.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Supplemental Figure 2: Combination of XVir-N-31 (XVir) and CDK4/6 inhibitor LEE011 (LEE) increases viral replication and immunogenicity of xenografted EwS tumors in vivo.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Supplemental Figure 1: Combination of XVir-N-31 and CDK4/6 inhibition increases oncolysis, viral particle formation associated by RB downregulation.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Supplemental Figure 1: Combination of XVir-N-31 and CDK4/6 inhibition increases oncolysis, viral particle formation associated by RB downregulation.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Supplemental Figure 5: Combination therapy of XVir-N-31 and CDK4/6 inhibitor LEE011 induces calreticulin (CALR) surface expression and increases phagocytosis in vitro.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Supplemental Figure 5: Combination therapy of XVir-N-31 and CDK4/6 inhibitor LEE011 induces calreticulin (CALR) surface expression and increases phagocytosis in vitro.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Purpose:Ewing sarcoma (EwS) is a highly malignant pediatric tumor characterized by a non-T-cell-inflamed immune-evasive phenotype. When relapsed or metastasized, survival is poor, emphasizing the need for novel treatment strategies. Here, we analyze the novel combination approach using the YB-1-driven oncolytic adenovirus XVir-N-31 and CDK4/6 inhibition to augment EwS immunogenicity.Experimental Design:In vitro, viral toxicity, replication, and immunogenicity were studied in several EwS cell lines. In vivo tumor xenograft models with transient humanization were applied to evaluate tumor control, viral replication, immunogenicity, and dynamics of innate as well as human T cells after treatment with XVir-N-31 combined with CDK4/6 inhibition. Furthermore, immunologic features of dendritic cell maturation and T-cell-stimulating capacities were assessed.Results:The combination approach significantly increased viral replication and oncolysis in vitro, induced HLA-I upregulation, and IFNγ-induced protein 10 expression and enhanced maturation of monocytic dendritic cells with superior capacities to stimulate tumor antigen-specific T cells. These findings were confirmed in vivo showing tumor infiltration by (i) monocytes with antigen-presenting capacities and M1 macrophage marker genes, (ii) TReg suppression in spite of adenovirus infection, (iii) superior engraftment, and (iv) tumor infiltration by human T cells. Consequently, survival was improved over controls with signs of an abscopal effect after combination treatment.Conclusions:The joint forces of the YB-1-driven oncolytic adenovirus XVir-N-31 and CDK4/6 inhibition induce therapeutically relevant local and systemic antitumor effects. Innate as well as adaptive immunity against EwS is boosted in this preclinical setting, pointing toward high therapeutic potential in the clinic.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Purpose:Ewing sarcoma (EwS) is a highly malignant pediatric tumor characterized by a non-T-cell-inflamed immune-evasive phenotype. When relapsed or metastasized, survival is poor, emphasizing the need for novel treatment strategies. Here, we analyze the novel combination approach using the YB-1-driven oncolytic adenovirus XVir-N-31 and CDK4/6 inhibition to augment EwS immunogenicity.Experimental Design:In vitro, viral toxicity, replication, and immunogenicity were studied in several EwS cell lines. In vivo tumor xenograft models with transient humanization were applied to evaluate tumor control, viral replication, immunogenicity, and dynamics of innate as well as human T cells after treatment with XVir-N-31 combined with CDK4/6 inhibition. Furthermore, immunologic features of dendritic cell maturation and T-cell-stimulating capacities were assessed.Results:The combination approach significantly increased viral replication and oncolysis in vitro, induced HLA-I upregulation, and IFNγ-induced protein 10 expression and enhanced maturation of monocytic dendritic cells with superior capacities to stimulate tumor antigen-specific T cells. These findings were confirmed in vivo showing tumor infiltration by (i) monocytes with antigen-presenting capacities and M1 macrophage marker genes, (ii) TReg suppression in spite of adenovirus infection, (iii) superior engraftment, and (iv) tumor infiltration by human T cells. Consequently, survival was improved over controls with signs of an abscopal effect after combination treatment.Conclusions:The joint forces of the YB-1-driven oncolytic adenovirus XVir-N-31 and CDK4/6 inhibition induce therapeutically relevant local and systemic antitumor effects. Innate as well as adaptive immunity against EwS is boosted in this preclinical setting, pointing toward high therapeutic potential in the clinic.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone decreases colony formation capacity in bladder cancer cell lines. Cells seeded in six-well plates were treated with increasing concentrations of amiodarone (0–5 μmol/L). After incubation for 7 to 10 days, the cells were stained with crystal violet, and the plates were scanned. A, Representative images of the colonies. B, Quantification of the colony number. Data are presented as the number of colonies related to the control and represent mean ± SEM from three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone decreases colony formation capacity in bladder cancer cell lines. Cells seeded in six-well plates were treated with increasing concentrations of amiodarone (0–5 μmol/L). After incubation for 7 to 10 days, the cells were stained with crystal violet, and the plates were scanned. A, Representative images of the colonies. B, Quantification of the colony number. Data are presented as the number of colonies related to the control and represent mean ± SEM from three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone reduces bladder cancer tumor growth in vivo. Tumor growth in BFTC905-bearing NOD/SCID mice treated with 75 mg/kg of amiodarone. A, Tumor volume over time in control (n = 6) and amiodarone-treated (n = 6) tumor-bearing animals during a 3-week cycle treatment. Data represent mean ± SEM (Student t test; **, P < 0.01). B, Body weight of control and amiodarone-treated animals after 27 days of the experiment. Data represent mean ± SEM (Student t test; ****, P < 0.0001). C, Histologic analysis of liver, kidney, and heart sections derived from control and amiodarone-treated animals. Representative hematoxylin and eosin images are shown. D, Heatmap of the top 20 upregulated and top 20 downregulated genes identified by RNA-seq expression analysis of xenograft tumor samples. E, Top 10 significantly deregulated pathways identified by the RNA-seq analysis. F, Gene set enrichment analysis barcode plots for the top five significantly deregulated pathways. G, Heatmap showing the expression of the apoptosis-inducing ligand TNFSF10 and mitochondrially encoded genes of the electron transport chain. H, Dot plot representing the apoptosis gene set activity score derived from RNA-seq gene expression data. FC, fold change.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone reduces bladder cancer tumor growth in vivo. Tumor growth in BFTC905-bearing NOD/SCID mice treated with 75 mg/kg of amiodarone. A, Tumor volume over time in control (n = 6) and amiodarone-treated (n = 6) tumor-bearing animals during a 3-week cycle treatment. Data represent mean ± SEM (Student t test; **, P < 0.01). B, Body weight of control and amiodarone-treated animals after 27 days of the experiment. Data represent mean ± SEM (Student t test; ****, P < 0.0001). C, Histologic analysis of liver, kidney, and heart sections derived from control and amiodarone-treated animals. Representative hematoxylin and eosin images are shown. D, Heatmap of the top 20 upregulated and top 20 downregulated genes identified by RNA-seq expression analysis of xenograft tumor samples. E, Top 10 significantly deregulated pathways identified by the RNA-seq analysis. F, Gene set enrichment analysis barcode plots for the top five significantly deregulated pathways. G, Heatmap showing the expression of the apoptosis-inducing ligand TNFSF10 and mitochondrially encoded genes of the electron transport chain. H, Dot plot representing the apoptosis gene set activity score derived from RNA-seq gene expression data. FC, fold change.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone inhibits mTOR and MAPK pathways. Cells were treated for 24 hours with increasing concentrations of amiodarone (0, 12.5, and 25 μmol/L), and the expression of the proteins AKT, mTOR, S6, and p44/42 MAPK, both phosphorylated (p-) and total, was analyzed by Western blot. GAPDH was used as a loading control. Blots are representative of three independent experiments. Quantification of the protein expression (normalized by GAPDH) is indicated under each corresponding band. Values are presented as expression related to the control. n.d., not determined.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone inhibits mTOR and MAPK pathways. Cells were treated for 24 hours with increasing concentrations of amiodarone (0, 12.5, and 25 μmol/L), and the expression of the proteins AKT, mTOR, S6, and p44/42 MAPK, both phosphorylated (p-) and total, was analyzed by Western blot. GAPDH was used as a loading control. Blots are representative of three independent experiments. Quantification of the protein expression (normalized by GAPDH) is indicated under each corresponding band. Values are presented as expression related to the control. n.d., not determined.